The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study

Anton L. V. Avanceña1,2 · James G. Kahn2,3,4,5 · Elliot Marseille2,6

Accepted: 26 January 2022 / Published online: 1 March 2022 © The Author(s) 2022

Abstract

Background and Objective Intensive psychotherapy assisted with 3,4-methylenedioxymethamphetamine (MDMA-AT) was shown in Phase 3 clinical trials to substantially reduce post-traumatic stress disorder (PTSD) symptoms compared to psychotherapy with placebo. This study estimates potential costs, health benefits, and net savings of expanding access to MDMA-AT to eligible US patients with chronic and severe PTSD.

Methods Using a decision-analytic model, we compared the costs, deaths averted, and quality-adjusted life years (QALYs) gained of three, 10-year MDMA-AT coverage targets (25%, 50%, and 75%) compared to providing standard of care to the same number of eligible patients with chronic and severe PTSD. We used a payer perspective and discounted costs (in US$) and QALYs to 2020. We conducted one-way, scenario, and probabilistic sensitivity analyses and calculated the net monetary value of MDMA-AT using a cost-effectiveness threshold of $100,000 per QALY gained.

Results Expanding access to MDMA-AT to 25–75% of eligible patients is projected to avert 43,618–106,932 deaths and gain 3.3–8.2 million discounted QALYs. All three treatment targets are dominant or cost-saving compared to standard of care. Our sensitivity analyses found that accounting for parameter uncertainty and changes in various assumptions did not alter the main finding—MDMA-AT is dominant compared to standard of care.

Conclusion Expanding access to MDMA-AT to patients with chronic and severe PTSD will provide substantial health and financial benefits. The precise magnitude is uncertain and will depend on the number of eligible patients and other inputs.
1 Introduction

Post-traumatic stress disorder (PTSD) is a highly debilitating psychiatric condition that adversely affects mood, cognition, physical and emotional health, and can lead to suicidal ideation and behavior [1–4]. In any given year, 3.5–4.7% of US adults or about 7.3–9.8 million individuals experience PTSD. Among military veterans, current prevalence of PTSD is as high as 13%, although some cohorts of combat veterans have reported PTSD prevalence as high as 20% [5–8]. PTSD is associated with healthcare costs and service utilization that are higher than those of other mental health conditions [9–15].

While about half of people with PTSD achieve recovery or remission spontaneously or following standard of care (SoC) [16–18], the remainder suffer from chronic and severe forms of PTSD which require long-term treatment. Existing Food and Drug Administration (FDA)-approved pharmacotherapies, sertraline and paroxetine, however, have limited effectiveness and unwanted side effects [19–21]. Recently, a new treatment for PTSD involving 3,4-methylenedioxymethamphetamine (MDMA), a currently illegal psychedelic agent, combined with psychotherapy was shown in a multisite, Phase 3 randomized clinical trial to be significantly more effective in reducing PTSD symptoms than placebo with same course of psychotherapy in patients with severe or extreme PTSD. The trial also found that MDMA-assisted therapy (MDMA-AT) did not increase suicidal ideation and other adverse events, even among those with comorbidities such as dissociation and depression [22]. With such promising results, the FDA could approve MDMA-AT for PTSD by 2023 [23].

Previous cost-effectiveness analyses have shown that MDMA-AT is dominant, which means that it generates more health benefits and has lower net costs than SoC, even under conservative assumptions regarding the benefits of treatment [24, 25]. In this study, we aim to estimate the costs, health benefits, and net savings of increased access to MDMA-AT among US adult patients with chronic and severe PTSD.

2 Methods

2.1 Overview

Following the Consolidated Health Economic Evaluation Reporting Standards and guidelines from the 2nd Panel on Cost-effectiveness in Health and Medicine [26, 27], we developed a decision-analytic model that simulates a closed cohort of about 3.5 million adult patients (i.e., excluding incident cases) with chronic and severe PTSD who are eligible for MDMA-AT based on the inclusion and exclusion criteria used in the Phase 3 trial [22]. We used a payer perspective and discounted future costs and benefits using a 3% yearly rate over a 30-year time horizon in the base-case analysis. The model, which was programmed in Microsoft Excel® (Microsoft Corp, Redmond, WA), uses annual cycles.

We modeled three hypothetical MDMA-AT treatment targets: 25%, 50%, and 75% (Fig. 1). These targets were selected because they are within the Healthy People 2030 goal for the proportion of adults with serious mental illness who receive treatment [28]. From year to year, the proportion of treated patients with chronic and severe PTSD nearly doubles until each cumulative target is reached at the end of 10 years. Our approach in constructing these treatment targets is based on previous modeling studies on the costs and benefits of scaling up mental health treatment services [29, 30].

Fig. 1 Cumulative proportion of eligible patients with chronic and severe PTSD who received with MDMA-AT over 10 years under three treatment targets. MDMA-AT 3,4-methylenedioxymethamphetamine assisted-therapy, PTSD post-traumatic stress disorder.
Cost-effectiveness of Expanding MDMA-AT in the USA

2.2 Data Sources

Data for the model (Table 1) were based on secondary sources. A full description of our estimation methods is presented in the Supplement.

2.2.1 Patients Eligible for MDMA-AT

We estimated the number of adult patients with chronic and severe PTSD who are eligible for MDMA-AT (Fig. 2) using published sources (see Electronic Supplementary Material).

Table 1 Model inputs

| Distribution of patients with PTSD who receive MDMA-AT by severity | Base value (range) | Distribution in PSA | Source |
|---|---|---|---|
| Asymptomatic | 33.3 | NA | [24] |
| Mild | 26.2 | NA | [24] |
| Moderate | 26.2 | NA | [24] |
| Severe | 11.9 | NA | [24] |
| Extreme | 2.4 | NA | [24] |
| Dead | 0 | NA | [24] |

| Distribution of patients with PTSD who receive standard of care by severity | Base value (range) | Distribution in PSA | Source |
|---|---|---|---|
| Asymptomatic | 0 | NA | [24] |
| Mild | 0 | NA | [24] |
| Moderate | 0 | NA | [24] |
| Severe | 71.4 | NA | [24] |
| Extreme | 28.3 | NA | [24] |
| Dead | 0 | NA | [24] |

| Costs (in 2020 US$) | Base value (range) | Distribution in PSA | Source |
|---|---|---|---|
| MDMA-AT (one-time) | 11,537 (8076–14,998) | Gamma | [55, 56] |
| Standard of care | 0 (0–13,256) | Gamma | [55, 56] |
| Medical care for asymptomatic PTSD | 5032 (3608–6456) | Gamma | [57–60] |
| Medical care for mild PTSD | 10,118 (7250–12,986) | Gamma | [57–60] |
| Medical care for moderate PTSD | 15,177 (10,855–19,469) | Gamma | [57–60] |
| Medical care for severe PTSD | 20,236 (14,512–25,960) | Gamma | [57–60] |
| Medical care for extreme PTSD | 24,283 (17,415–31,151) | Gamma | [57–60] |

| Health utilities | Base value (range) | Distribution in PSA | Source |
|---|---|---|---|
| Asymptomatic | 0.90 (0.81–0.99) | Beta | [24] |
| Mild | 0.83 (0.75–0.91) | Beta | [24] |
| Moderate | 0.74 (0.67–0.81) | Beta | [24] |
| Severe | 0.61 (0.55–0.67) | Beta | [24] |
| Extreme | 0.37 (0.33–0.41) | Beta | [24] |
| Dead | 0 | NA | Assumed |

| Other inputs and assumptions | Base value (range) | Distribution in PSA | Source |
|---|---|---|---|
| Cohort size (range) | 3,523,049 (2,110,743–4,735,640) | Normal | [16–18, 31–33] |
| Annual discount rate (%) | 3 (0.23–0.38) | Beta | Assumed |
| Time horizon (years) | 30 (10–40) | Uniform | Assumed |
| Mean age of cohort | 41 | NA | [22] |
| Probability of death from all causes | 0.002 (0.0018–0.0022) | Beta | [61] |

MDMA-AT 3,4-methylenedioxymethamphetamine assisted-therapy, NA not applicable, PSA probabilistic sensitivity analysis, PTSD post-traumatic stress disorder

*Base-case value and range calculated by authors using the references listed

**Costs are annual unless otherwise noted
state-transition model developed by two of the current authors that estimated the health and economic outcomes beyond the 8-week time horizon of the Phase 3 trial (Fig. 3) [24]. In addition to deceased, the health states in the model were asymptomatic, mild, moderate, severe, and extreme PTSD, which are based on patient scores on the most recent iteration of the Clinician-Administered PTSD Scale.

Previous studies estimate that the proportion of people with PTSD who experience a chronic and severe form is 50% (range 40–60%) [16–18]. Of this population, about 21.9% (range 12.5–41.5%) would be ineligible for MDMA-AT because of psychiatric and medical comorbidities such as any current substance use disorder, primary psychotic disorder, and bipolar disorder according to the inclusion criteria of the Phase 3 trial [33]. Thus, in the base-case analysis we assumed that the number of eligible patients is 3,523,049 (range: 2,110,743–4,735,640).

2.2.2 Transition Probabilities

We based transition probabilities on the results of our previous modeling study [24]. We used a previously published trials of MDMA-AT. MDMA-AT methylenedioxymethamphetamine-assisted psychotherapy, PTSD post-traumatic stress disorder [ESM]). Citing national survey data, the National Institute for Mental Health states that the past-year prevalence of PTSD among US adults is 3.6% [31]. Since there are 250,563,000 people aged ≥ 18 years in 2019 [32], we estimated that the number of adults with PTSD is 9,020,268.

Our prior study produced “Markov traces,” or distributions of 1000 simulated patients across health states, for those who received MDMA-AT and SoC (Fig. S1–S2 and Tables S1–S2 in ESM). We used these traces to portray the proportion of simulated patients in each health state over time. For example, 71.4% of simulated patients who receive SoC start from the severe PTSD health state, while 28.6% begin from the extreme PTSD health state (Table 1). These patients progress to other health states based on the Markov trace for this population (Fig. S2 in ESM). Similarly, patients who receive MDMA-AT start from the asymptomatic (33.3%), mild (26.2%), moderate state-transition model developed by two of the current authors that estimated the health and economic outcomes beyond the 8-week time horizon of the Phase 3 trial (Fig. 3) [24]. In addition to deceased, the health states in the model were asymptomatic, mild, moderate, severe, and extreme PTSD, which are based on patient scores on the most recent iteration of the Clinician-Administered PTSD Scale.

Our prior study produced “Markov traces,” or distributions of 1000 simulated patients across health states, for those who received MDMA-AT and SoC (Fig. S1–S2 and Tables S1–S2 in ESM). We used these traces to portray the proportion of simulated patients in each health state over time. For example, 71.4% of simulated patients who receive SoC start from the severe PTSD health state, while 28.6% begin from the extreme PTSD health state (Table 1). These patients progress to other health states based on the Markov trace for this population (Fig. S2 in ESM). Similarly, patients who receive MDMA-AT start from the asymptomatic (33.3%), mild (26.2%), moderate

![Fig. 2](image1.jpg)

Flow diagram summarizing the process for estimating the number of patients with chronic and severe PTSD who are eligible for MDMA-AT based on the eligibility criteria used in the Phase 3 trials.

![Fig. 3](image2.jpg)

Root of the schematic shows the four decision alternatives or scenarios—standard of care and the three MDMA-AT treatment targets (25%, 50%, and 75% of eligible patients). The shaded purple circle denotes the common Markov node, and the ovals are the PTSD states that simulated patients transition to. Each PTSD state is associated with a cost and health utility. Arrows represent transitions and are associated with an annual probability. Asym asymptomatic, Ext extreme, MDMA-AT methylenedioxymethamphetamine-assisted psychotherapy, Mod moderate, PTSD post-traumatic stress disorder, Sev severe.
The costs of medical care refer to all healthcare costs incurred by patients with PTSD in a year; these care costs are positively associated with PTSD severity according to the severity of PTSD; thus, the results are determined by the proportion of patients in each severity category over time.

We assume that patients with PTSD are treated with the same MDMA-AT protocol as in the Phase 3 trial [19, 22, 34], and that they experience the same level of efficacy modeled in the prior study in the base-case analysis. While the long-term efficacy of MDMA-AT is still unknown, limited research suggests that remission from severe PTSD symptoms among patients who receive MDMA-AT was maintained for a follow-up period averaging 3.5 years following treatment [35]. In scenario analysis, we reduce the efficacy of MDMA-AT to understand the effect of this assumption on our results.

2.2.3 Costs

We included two main healthcare-related costs: the cost of MDMA-AT and the cost of medical care for patients with PTSD (Table 1). We briefly describe our methods for estimating these costs below, and full details are provided elsewhere [24]. All costs are in 2020 US$. The one-time cost of MDMA-AT ($11,537, range: $8076–14,998; Table 1) was based on a previous micro-costing of the resources required to deliver MDMA-AT per protocol, including three 90-min preparatory psychotherapy sessions, three 8-h MDMA sessions, and nine 90-min integration sessions. All sessions are conducted with one patient and two clinicians.

The cost of medical care refers to all healthcare costs incurred by patients with PTSD in a year; these care costs are positively associated with PTSD severity according to previous research [36]. The costs of medical care for different PTSD severity levels were derived from estimates in the peer-reviewed literature (Table 1). In the base-case analysis, we assumed that the costs of SoC are included in medical care costs, although we varied this assumption in the sensitivity analyses.

2.2.4 Health Outcomes

The outcomes of interest in this study were deaths averted and quality-adjusted life years (QALYs) gained. QALYs combine length and quality of life and are the preferred health outcome in economic evaluations for health in developed countries [37]. QALYs in this study incorporate health utilities that were calculated using EQ-5D-5L scores of participants in the MDMA-AT Phase 3 trial (Table 1) [24]. Respondent scores on the EQ-5D-5L are converted to health utilities through a valuation method that uses preference weights specific to the USA [38].
In PSA, we varied selected inputs simultaneously over 10,000 independent Monte Carlo trials using distributions that were assigned a priori (Table 1 and Table S3 in ESM). We summarized the results of the PSA in cost-effectiveness acceptability curves that plot the average probability that SoC and MDMA-AT have the highest NMV across a range of cost-effectiveness thresholds ($0–100,000 per QALY gained).

3 Results

3.1 Base-case

Between 780,000 and 1.41 million patients with PTSD receive MDMA-AT under the three treatment targets (Fig. S5 in ESM). Achieving the 50% target would avert an estimated 78,768 deaths and gain over 6 million discounted QALYs over 10 years (Table 2). Achieving the 25% target can save 43,618 lives and gain 3.3 million QALYs over 10 years. The 75% treatment target saves most lives (106,932) and gains the most QALYs (8.2 million) over 10 years.

In all three targets, the costs of expanding access to MDMA-AT to eligible patients is less than the costs of providing SoC to the same number of patients. As a result, all three treatment targets are dominant (i.e., cost-saving while producing health benefits).

3.2 One-way Sensitivity Analysis

One-way sensitivity analysis found that using the highest and lowest values of various inputs in our model did not change the main finding that MDMA-AT is dominant when compared to SoC (Tables S4–S6 in ESM).

3.3 Scenario Analysis

The results of the scenario analyses are found in Table S7 in ESM. We found that reducing the effectiveness of MDMA-AT or increasing the effectiveness of SoC does not change the main finding that MDMA-AT is dominant in all three treatment targets.

3.4 Probabilistic Sensitivity Analysis

Across 10,000 independent simulations, we found that MDMA-AT is dominant compared to SoC, and the average results (Table S8 in ESM) were similar to our base-case findings (Table 2). The results of the PSA are further summarized in cost-effectiveness planes (Fig. S9–S11 in ESM) and cost-effectiveness acceptability curves (Fig. S12–S14 in ESM). After accounting for multi-parameter uncertainty, MDMA-AT under any treatment target was found to be the optimal choice (i.e., provide greater NMV) 100% of the time across various cost-effectiveness thresholds.

4 Discussion

This study estimated the economic and public health benefits of MDMA-AT for treating chronic and severe PTSD. We found that expanding access to MDMA-AT to 25–75%
of eligible patients over 10 years would avert between 43,618–106,932 deaths, produce 3.3–8.2 million discounted QALYs, and lead to $109–$266 billion in discounted savings for the healthcare system.

The findings from this study suggest that MDMA-AT is comparable to other widely used therapies in the USA. For example, the number of deaths averted by expanding access to MDMA-AT is higher than the estimated number of suicides prevented by the availability of fluoxetine for depression (33,600, credible interval 22,400–45,000) [39]. The number of QALYs gained through MDMA-AT is more than antiretroviral therapy during the first few years of the HIV/AIDS epidemic (2.95 million) [40] or achieving national targets for HIV testing and treatment over 20 years (2.14 million) [41]. Finally, the costs savings we estimated in this study are comparable to the direct medical expenditures that can be averted by access to smoking cessation programs [42, 43].

Our study builds on two economic evaluations of MDMA-AT that demonstrated the value of this intervention. Using pooled results from six Phase 2 trials [19], one study estimated that MDMA-AT for 1000 patients with PTSD can generate $103.2 million in net savings and 5553 QALYs over 30 years when compared to SoC [25]. Under the most conservative assumption that benefit ceases after 12 months, the ICER is $26,427 per QALY gained, significantly lower than the $100,000 per QALY gained threshold that is commonly used to evaluate the efficiency of health interventions in the USA [37]. A more recent study used data from the Phase 3 trial of MDMA-AT, which involved one additional MDMA session than in the Phase 2 trial, and found that providing 1000 patients with PTSD access to MDMA-AT would save the healthcare system approximately $132.9 million while averting 61.4 premature deaths and generating 4856 QALYs over 30 years [24].

Our study also finds that MDMA-AT is cost-saving under a range of assumptions, although expanding access to MDMA-AT requires significant initial outlay. To realize the savings we estimated from this study, public and private payers, health systems, and government will have to invest in human resources to administer MDMA-AT. For example, the Phase 3 trial protocol involved 15 sessions with two trained therapists, which means that treating 25–75% of eligible patients with MDMA-AT (as we modeled in this study) will require training and certifying thousands of therapists.

As with any new therapy, other scientific, political, and legal factors will also shape the speed and scale in which MDMA-AT will be adopted [44]. Multidisciplinary Association for Psychedelic Studies (MAPS), the Phase 3 trial sponsor, obtained an FDA “breakthrough therapy” designation for MDMA-AT in 2017, which promises to expedite development and review processes [45]. Although not required by the FDA, MAPS is currently enrolling subjects for an additional Phase 3 trial and expects to apply for full FDA approval for MDMA-AT by 2023 [23].

Federal and state action is also needed to fully legalize the production and prescription of MDMA-AT. Congress or the Drug Enforcement Administration, for instance, may fully deschedule MDMA, as was done for cannabidiol in 2018, a non-psychoactive ingredient found in cannabis that is used to produce the FDA-approved seizure medication Epidolex®. Descheduling would exempt MDMA from controlled substance restrictions, enable the FDA to regulate it as an approved therapeutic, and provide access to federal research dollars [46, 47]. FDA approval and descheduling of MDMA is also a necessary condition for private and public payers to include MDMA-AT as a benefit; thus, without such approvals, the level of access explored in the current analysis would be impossible.

Aside from supply-side factors, demand-side determinants will have to be addressed to achieve the savings and health benefits we estimated. For example, our model assumes that there are no financial barriers to care, and all those who are eligible and wish to receive treatment can do so via sufficient insurance coverage or self-financing. Additionally, our study assumes high levels of care-seeking and treatment adherence among people with PTSD, which may not reflect reality given the stigma around severe mental illness and other cognitive, cultural, economic, and logistical barriers to PTSD care, which have been documented in the literature [48–50].

4.1 Limitations

This study has several limitations. First, there is uncertainty around the true number of eligible patients with chronic and severe PTSD for MDMA-AT. Estimates of the number of people with PTSD are limited and challenging to calculate because PTSD cases, like many mental illnesses that are highly stigmatized, are often underreported. There are also no precise estimates of the proportion of PTSD cases that are chronic and severe, and, among these cases, no studies to our knowledge have estimated the prevalence of comorbidities that would make patients ineligible for MDMA-AT. For this study, we used the prevalence of any current alcohol and substance use disorder, which is the most common comorbidity in PTSD patients, to determine the proportion of cases that would be ineligible for MDMA-AT. However, we used data from the Veterans Administration, and the prevalence from that patient population may be different from that of the broader public. Additional research is needed to refine this input.

Second, we modeled a closed cohort of patients with chronic and severe PTSD, and we have likely underestimated the benefits of access to MDMA-AT over the time
horizon of our study. Future studies should include incident (in addition to prevalent) cases of PTSD, although estimates of the incidence of PTSD are limited and often focus on specific groups of people that experience a traumatic event, such as a natural disaster or acute violent episodes [51–53]. Third, we used a healthcare payer perspective, and future analyses should use a societal perspective that include other sources of costs and benefits, such as patient time costs, travel costs, caregiver burden, and lost productivity and consumption [26].

Fourth, our model relies primarily on the inputs and findings of a previous cost-effectiveness analysis, which means that limitations from that study carry over to our current study. For example, Marseille et al assumed that patients with PTSD who receive SoC experience no improvements in their disease severity. This assumption is supported by evidence that chronic and severe PTSD is highly treatment-resistant, and that spontaneous remission in PTSD is limited to the first years following diagnosis [17, 22, 35, 54]. In addition, we assumed that the efficacy of MDMA-AT is durable, which is supported by limited research showing that patients who have received MDMA-AT maintain statistically and clinically significant improvements in their severe PTSD symptoms for years following treatment [35]; however, the true long-term efficacy of MDMA-AT remains unknown. We conducted scenario analyses to relax these assumptions, and future studies should further explore the effect of these assumptions on the efficiency of MDMA-AT.

Finally, the generalizability of our results is limited by the underlying Phase 3 trial which (1) only evaluated the short-term efficacy of MDMA-AT and (2) involved participants who do not necessarily represent the diversity of the US patients with chronic and severe PTSD.

5 Conclusion

MDMA-AT has the potential to significantly improve PTSD care nationwide. Increased access to this therapy can save and extend lives of patients with chronic and severe PTSD, as well as reduce healthcare costs.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40261-022-01122-0.

Declarations

Funding No funding was received to conduct this study.

Conflicts of interest All authors have no conflict of interest to declare.

Ethics approval Not applicable.

Consent to publish Not applicable.

Consent to participate Not applicable.

Availability of data and materials Data needed to replicate this study are found in the main text, cited references, and in the electronic supplementary material.

Code availability Not applicable.

Author contributions ALVA validated, curated, analyzed, and interpreted the data, wrote the first draft of the manuscript, edited the manuscript, and is the guarantor of the study. JGK conceptualized the study, edited the manuscript, and provided oversight. EM conceptualized the study, curated, analyzed, and interpreted the data, edited the manuscript, and provided oversight and supervision. All authors approve the submission and publication of the manuscript.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. J Trauma Stress. 2013;26:537–47.
2. Goldstein RB, Smith SM, Chou SP, Saha TD, Jung J, Zhang H, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016;51:1137–48.
3. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–27.
4. Nichter B, Norman SB, Maguen S, Pietrzak RH. Moral injury and suicidal behavior among US combat veterans: Results from the 2019–2020 National Health and Resilience in Veterans Study. Depress Anxiety. 2021;38:606–14.
5. Steenkamp MM, Litz BT, Hoge CW, Marmar CR. Psychotherapy for military-related PTSD: A review of randomized clinical trials. JAMA. 2015;314:489–500.
6. Seal KH, Bertenthal D, Miner CR, Sen S, Marmar C. Bringing the war back home: mental health disorders among 103 788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs facilities. Arch Intern Med. 2007;167:476.
7. Dursa EK, Reinhard MJ, Barth SK, Schneiderman AI. Prevalence of a Positive Screen for PTSD Among OEF/OIF and OEF/OIF-Era Veterans in a Large Population-Based Cohort. J Trauma Stress. 2014;27:542–9.
8. Helzer JE, Robins LN, McEvoy L. Post-traumatic stress disorder in the general population: findings of the Epidemiologic Catchment Area Survey. N Engl J Med. 1987;317:1630–4.

9. von der Wardt R, Dams J, Grochtdreis T, König H-H. Economic evaluations and cost analyses in posttraumatic stress disorder: a systematic review. Eur J Psychotraumatol. 2020;11:1753940.

10. Haviland MG, Banta JE, Sonne JL, Przekop P. Posttraumatic stress disorder–related hospitalizations in the United States (2002–2011): rates, co-occurring illnesses, suicidal ideation/self-harm, and hospital charges. J Nerv Ment Dis. 2016;204:78–86.

11. Kartha A, Brower V, Saiz R, Samet JH, Keane TM, Liebschutz J. The impact of trauma exposure and post-traumatic stress disorder on healthcare utilization among primary care patients. Med Care. 2008;46:388–93.

12. Vyas KJ, Fesperman SF, Nebeker BJ, Gerard SK, Boyd ND, Delaney EM, et al. Preventing PTSD and depression and reducing healthcare costs in the military: a call for building resilience among service members. Mil Med. 2016;181:1240–7.

13. Tuerk PW, Wangelin B, Rauch SAM, Dismuke CE, Yoder M, Myrick H, et al. Health service utilization before and after evidence-based treatment for PTSD. Psychol Serv. 2013;10:401–9.

14. Outcalt SD, Yu Z, Hoen HM, Pennington TM, Krebs EE. Health care utilization among veterans with pain and posttraumatic stress symptoms. Pain Med. 2014;15:1872–9.

15. Kaefer E, Possemato K, Lantinga LJ, Maisto SA, Ouimette P. Associations between PTSD and healthcare utilization among OEF/OIF veterans with hazardous alcohol use. Traumatology. 2014;20:142–9.

16. Steinert C, Hofmann M, Leichsenring F, Kruse J. The course of PTSD in naturalistic long-term studies: high variability of outcomes. A systematic review. Nord J Psychiatry. 2015;69:483–96.

17. Morina N, Wicherts JM, Lobbrecht J, Priebe S. Remission from PTSD in naturalistic studies: evidence of variability of outcome. PLoS One. 2012;7:e42135.

18. Koek RJ, Schwartz HN, Scully S, Lande D, Kazmaier M, Walsh Z, et al. Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:170–218.

19. Mittoefer MC, Feduccia AA, Jerome L, Mittoefer A, Wagner M, Walsh Z, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for Phase 3 trials based on pooled analysis of six Phase 2 randomized controlled trials. Psychopharmacology. 2019;236:2735–45.

20. Institute of Medicine. Treatment for posttraumatic stress disorder in military and veteran populations: final assessment. Washington, D.C.: National Academies Press; 2014.

21. Bradley R, Greene J, Russ E, Dutra L. A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005;162:214–27.

22. Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled Phase 3 study. Nat Med. 2021;27:1025–33.

23. Multidisciplinary Association for Psychedelic Studies. MDMA-assisted psychotherapy. 2021. https://maps.org/research/mdma. Accessed 9 Jul 2021.

24. Marseille E, Mitchell JM, Kahn JG. Updated cost-effectiveness of MDMA-assisted therapy for the treatment of PTSD: findings from a Phase 3 trial. PLoS One. 2022 (In press).

25. Marseille E, Kahn JG, Yazar-Klosinski B, Doblin R. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLoS ONE. 2020;15:e0239997.
44. Jordans MJD, Kohrt BA. Scaling up mental healthcare and psychosocial support in low-resource settings: a roadmap to impact. Epidemiol Psychiatr Sci. 2018;29:e189.
45. Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry. 2019;10:650.
46. Congressional Research Service. State marijuana “legalization” and federal drug law: a brief overview for Congress. https://fas.org/sgp/crs/misc/LSB10482.pdf. Accessed 9 Jul 2021.
47. Haffajee R, Mauri A. Cannabis liberalization in the US: the policy landscape. Health Aff. 2021. https://www.healthaffairs.org/doi/10.1377/hpb20210518.36548/full/. Accessed 25 Feb 2022.
48. Kazlauskas E. Challenges for providing healthcare in traumatized populations: barriers for PTSD treatments and the need for new developments. Glob Health Action. 2017;10:1322399.
49. Sayer N, Friedemann-Sánchez G, Spoont M, Murdoch M, Parker L, Chiros C, et al. A qualitative study of determinants of PTSD treatment initiation. Psychiatry. 2009;72:238–55.
50. Lord S, Wagner A, Russo J, Love J, Zatzick D. Assessing barriers to care and readiness for cognitive behavioral therapy in early acute care PTSD interventions. Psychiatry. 2011;74:207–23.
51. Yule W, Bolton D, Udwin O, Boyle S, O’Ryan D, Nurrish J. The long-term psychological effects of a disaster experienced in adolescence: I: the incidence and course of PTSD. J Child Psychol Psychiatry. 2000;41:503–11.
52. Caldwell MF. Incidence of PTSD among staff victims of patient violence. Hosp Community Psychiatry. 1992;43:838–9.